Skip to main content
Clinical Trials/JPRN-UMIN000015369
JPRN-UMIN000015369
Completed
未知

The study of dapagliflozin (sodium glucose cotransporter 2 inhibitor) to verify the efficacy of combination therapy in Japanese patients with type 2 diabetes - DISCOVERY study

Okayama University Hospital nephrology, diabates and endocrinology0 sites100 target enrollmentOctober 8, 2014
ConditionsType 2 diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
Type 2 diabetes
Sponsor
Okayama University Hospital nephrology, diabates and endocrinology
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 8, 2014
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Okayama University Hospital nephrology, diabates and endocrinology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) type 1 diabetes 2\) BMI: \>\= 45 3\) patients suspected of pregnancy or pregnant or nursing 4\) diabetes insipidus 5\) severe liver dysfunction (liver cirrhosis, viral hepatitis, AST: \>\= 3 times of upper limit) 6\) moderate renal dysfunction (eGFR: \< 45 ml/min/1\.73m2\) 7\) heart disease (myocardial infarction, unstable angina) or stroke within 3 months 8\) considered as inadequate by the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials